Braveheart Bio targets $382 million IPO to fund cardiac drug development

Braveheart Bio announced an upsized initial public offering on the Nasdaq, aiming to raise about $382.5 million. The company will sell 21.2 million shares at $18 each under the ticker BRVE.

The proceeds are intended to advance its lead candidate, BHB-1893, an oral small-molecule inhibitor of cardiac myosin for hypertrophic cardiomyopathy. The therapy is moving toward late-stage clinical testing.

This IPO marks the 22nd biotech listing this year, expanding the market after earlier offerings from Attovia and Vogenx. Braveheart’s entry adds further capital to the cardiovascular-focused sector.